Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease
Anderson et al.
, Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19..
, Infectious Diseases and Therapy, doi:10.1007/s40121-020-00316-3 (In Vitro)
study showing rapid and effective virucidal activity of PVP-I
against SARS-CoV-2. All four products tested [antiseptic solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved C 99.99% virucidal activity against SARS-CoV-2, corresponding to C 4 log10 reduction of virus titre, within 30s of contact.8 In Vitro studies
support the efficacy of povidone-iodine [Anderson, Bidra, Frank, Hassandarvish, Meister, Pelletier, Tucker, Xu]
Anderson et al., 8 Jul 2020, peer-reviewed, 8 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: Infect Dis Ther (2020) 9:669–675
Povidone-Iodine Demonstrates Rapid In Vitro
Virucidal Activity Against SARS-CoV-2, The Virus
Causing COVID-19 Disease
Danielle E. Anderson . Velraj Sivalingam . Adrian Eng Zheng Kang .
Abhishek Ananthanarayanan . Harsha Arumugam . Timothy M. Jenkins .
Yacine Hadjiat . Maren Eggers
Received: June 2, 2020 / Published online: July 8, 2020
Ó The Author(s) 2020
Introduction: As of 22 June 2020, Severe Acute
(CoV)-2 has infected more than 8.95 million
people worldwide, causing [ 468,000 deaths.
The virus is transmitted through respiratory
droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene
Danielle E. Anderson, Velraj Sivalingam and Adrian Eng
Zheng Kang contributed equally to this work.
Electronic supplementary material The online
version of this article (https://doi.org/10.1007/s40121020-00316-3) contains supplementary material, which is
available to authorized users.
Digital Features To view digital features for this article
go to https://doi.org/10.6084/m9.figshare.12555317.
D. E. Anderson (&) V. Sivalingam A. E. Z. Kang
Programme in Emerging Infectious Diseases, DukeNUS Medical School, Singapore, Singapore
A. Ananthanarayanan H. Arumugam Y. Hadjiat
Mundipharma Singapore Holding Pte. Limited,
T. M. Jenkins
Mundipharma Research Limited, Cambridge
Science Park, Cambridge, UK
M. Eggers (&)
Labor Prof. Dr. G. Enders MVZ GbR, Stuttgart,
and oral decontamination among other measures are key to preventing the spread of the
virus. We report the in vitro virucidal activity of
topical and oral povidone-iodine (PVP-I) products against SARS-CoV-2.
Methods: Suspension assays were used to assess
the virucidal activity of PVP-I against SARSCoV-2. Products were tested at a contact time of
30 s for virucidal activity. Viral titres were calculated using the Spearman–Kärber method and
reported as median tissue culture infectious
Results: All four products [antiseptic solution
(PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle
and mouth wash (PVP-I 1%) and throat spray
(PVP-I 0.45%)] achieved C 99.99% virucidal
activity against SARS-CoV-2, corresponding to
C 4 log10 reduction of virus titre, within 30 s of
Conclusion: This study provides evidence of
rapid and effective virucidal activity of PVP-I
against SARS-CoV-2. PVP-I-based products are
widely available for medical and personal use
for hand hygiene and oral decontamination,
and could be readily integrated into coronavirus
disease, COVID-19, infection control measures
in hospital and community settings.
Keywords: Anti-infective agents; COVID-19;
Povidone-iodine; PVP-I; SARS-CoV-2; Upper
respiratory tract infections; Viruses
Infect Dis Ther (2020) 9:669–675
Key Summary Points
Why carry out this study?
To generate evidence of PVP-I virucidal
activity against SARS-CoV-2, the virus that
causes COVID-19 disease.
With no definitive treatment or vaccine
available as yet for COVID-19, effective
infection control measures are needed to
limit virus spread.
Previous studies showed the efficacy of
PVP-I products against similar viruses
(SARS-CoV, MERS-CoV) and a range of
other viruses, but PVP-I has not yet been
directly tested against SARS-CoV-2.
What was learned from the study?
All four tested PVP-I..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.